KR20210113271A - 콜라게나제 제형 및 이의 제조 방법 - Google Patents

콜라게나제 제형 및 이의 제조 방법 Download PDF

Info

Publication number
KR20210113271A
KR20210113271A KR1020217024557A KR20217024557A KR20210113271A KR 20210113271 A KR20210113271 A KR 20210113271A KR 1020217024557 A KR1020217024557 A KR 1020217024557A KR 20217024557 A KR20217024557 A KR 20217024557A KR 20210113271 A KR20210113271 A KR 20210113271A
Authority
KR
South Korea
Prior art keywords
formulation
collagenase
lyophilized
lys
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217024557A
Other languages
English (en)
Korean (ko)
Inventor
카루나카르 스쿠루
Original Assignee
엔도 글로벌 에스테틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엔도 글로벌 에스테틱스 리미티드 filed Critical 엔도 글로벌 에스테틱스 리미티드
Publication of KR20210113271A publication Critical patent/KR20210113271A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24003Microbial collagenase (3.4.24.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24007Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1020217024557A 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법 Ceased KR20210113271A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962788916P 2019-01-06 2019-01-06
US62/788,916 2019-01-06
PCT/US2020/012202 WO2020142701A1 (en) 2019-01-06 2020-01-03 Collagenase formulations and methods of producing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020267010947A Division KR20260051486A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
KR20210113271A true KR20210113271A (ko) 2021-09-15

Family

ID=69845512

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217024557A Ceased KR20210113271A (ko) 2019-01-06 2020-01-03 콜라게나제 제형 및 이의 제조 방법

Country Status (10)

Country Link
US (3) US20220305094A1 (https=)
EP (1) EP3906014A1 (https=)
JP (2) JP7565280B2 (https=)
KR (1) KR20210113271A (https=)
CN (1) CN113382714A (https=)
AU (2) AU2020204922B2 (https=)
BR (1) BR112021012675A2 (https=)
IL (2) IL321891A (https=)
MX (1) MX2021008017A (https=)
WO (1) WO2020142701A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172070A1 (ko) * 2022-03-08 2023-09-14 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN114264633B (zh) * 2022-02-10 2022-09-06 上海蓝长科技集团有限公司 一种福尔马肼聚合物冻干粉及制备方法
CN119656117B (zh) * 2024-12-18 2025-08-29 远大生命科学(鞍山)有限公司 一种药物组合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2921180B1 (en) * 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
CN101312744A (zh) 2005-11-22 2008-11-26 惠氏公司 免疫球蛋白融合蛋白制剂
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
ES2388219T3 (es) * 2008-06-02 2012-10-10 F. Hoffmann-La Roche Ag Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
JP2014530873A (ja) * 2011-10-21 2014-11-20 オーキシリウム インターナショナル ホールディングス,インコーポレイテッド Efpの治療または低減方法
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
EP3834840B8 (en) 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
CA3039655A1 (en) * 2016-10-07 2018-04-12 Regeneron Pharmaceuticals, Inc. Room temperature stable lyophilized protein
EP4591945A3 (en) * 2017-03-01 2026-04-15 Endo Operations Limited Apparatus and method for assessing and treating cellulite

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023172070A1 (ko) * 2022-03-08 2023-09-14 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신을 포함하는 조성물 및 콜라게네이즈의 안정화 방법
US12516310B2 (en) 2022-03-08 2026-01-06 CONNEXT Co., Ltd Composition comprising collagenase, calcium, histidine, and glycine, and method for stabilizing collagenase

Also Published As

Publication number Publication date
JP2022516569A (ja) 2022-02-28
IL321891A (en) 2025-09-01
AU2025204915A1 (en) 2025-07-24
AU2020204922B2 (en) 2025-04-24
IL284270A (en) 2021-08-31
JP7565280B2 (ja) 2024-10-10
MX2021008017A (es) 2021-08-05
CN113382714A (zh) 2021-09-10
JP2025016453A (ja) 2025-02-04
BR112021012675A2 (pt) 2021-09-28
CA3125007A1 (en) 2020-07-09
US20250249080A1 (en) 2025-08-07
WO2020142701A1 (en) 2020-07-09
US20240041993A1 (en) 2024-02-08
US20220305094A1 (en) 2022-09-29
IL284270B1 (en) 2025-08-01
US12303557B2 (en) 2025-05-20
AU2020204922A1 (en) 2021-07-01
EP3906014A1 (en) 2021-11-10
IL284270B2 (en) 2025-12-01

Similar Documents

Publication Publication Date Title
KR20210113271A (ko) 콜라게나제 제형 및 이의 제조 방법
JP6258674B2 (ja) クロストリジウム・ディフィシレトキソイドaおよびbを含有する薬学的組成物
AU2021250949A1 (en) Liquid Pharmaceutical Composition
Hackl et al. Effect of arginine on the aggregation of protein in freeze-dried formulations containing sugars and polyol: 1—formulation development
KR20260051486A (ko) 콜라게나제 제형 및 이의 제조 방법
CN121335712A (zh) 用于产生包含多克隆IgM的冻干组合物的方法及获得的组合物
TWI827694B (zh) 免疫蛋白酶體抑制劑調配物
Bjelošević et al. Effects of monoclonal antibody concentration and type of bulking agent on critical quality attributes of lyophilisates
CA3125007C (en) Collagenase formulations and methods of producing the same
HK40053714A (en) Collagenase formulations and methods of producing the same
US20250235515A1 (en) Clostridium botulinum neurotoxin serotype a compositions and improved drying processes
JP2023526024A (ja) Il-2融合ポリペプチド組成物ならびにその作製及び使用方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

V11 Administrative appeal requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-V10-V11-APL-PJ0201 (AS PROVIDED BY THE NATIONAL OFFICE)